Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

NCT07186842 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07186842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07186842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 18, 2025
Completion date
May 31, 2030
Enrollment
245 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancers